NASDAQ:HARPHarpoon Therapeutics Stock Price, Forecast & News

$21.69

-3.03 (-12.26 %)

(As of 05/27/2020 04:00 PM ET)

Add

Compare

Today's Range

$21.12

Now: $21.69▼

$24.93

50-Day Range

$11.11

MA: $13.92▼

$22.80

52-Week Range

$10.27

Now: $21.69▼

$25.02

Volume457,771 shs

Average Volume120,345 shs

Market Capitalization$542.21 million

P/E RatioN/A

Dividend YieldN/A

Beta0.84

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Harpoon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.00, Harpoon Therapeutics has a potential upside of 33.7% from its current price of $21.69.
Amount of Analyst Coverage
Harpoon Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.1 Community Rank

Outperform Votes
Harpoon Therapeutics has received 45 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Harpoon Therapeutics has received 60 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Harpoon Therapeutics has received 57.14% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Harpoon Therapeutics and other stocks. Vote “Outperform” if you believe HARP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HARP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Harpoon Therapeutics does not currently pay a dividend.
Dividend Growth
Harpoon Therapeutics does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harpoon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $299,637.00 in company stock.
Percentage Held by Insiders
Only 34.90% of the stock of Harpoon Therapeutics is held by insiders.
Percentage Held by Institutions
77.13% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Harpoon Therapeutics are expected to grow in the coming year, from ($1.97) to ($1.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harpoon Therapeutics is -9.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harpoon Therapeutics is -9.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Harpoon Therapeutics has a P/B Ratio of 6.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.45 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:HARP

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.harpoontx.com

Phone650-443-7400

Debt

Debt-to-Equity Ratio0.16

Current Ratio5.40

Quick Ratio5.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.78 million

Price / Sales93.81

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.33 per share

Price / Book6.51

Profitability

EPS (Most Recent Fiscal Year)($2.55)

Net Income$-55,570,000.00

Net Margins-681.41%

Return on Equity-53.62%

Return on Assets-34.20%

Miscellaneous

Employees45

Outstanding Shares24,998,000

Market Cap$542.21 million

Next Earnings Date8/3/2020 (Estimated)

OptionableNot Optionable

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.

Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

How has Harpoon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HARP shares have increased by 66.0% and is now trading at $21.69. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Harpoon Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Harpoon Therapeutics.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Harpoon Therapeutics.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics Inc (NASDAQ:HARP) posted its earnings results on Wednesday, May, 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.11. The company earned $3.30 million during the quarter, compared to analysts' expectations of $7.58 million. Harpoon Therapeutics had a negative net margin of 681.41% and a negative return on equity of 53.62%. View Harpoon Therapeutics' earnings history.

What price target have analysts set for HARP?

5 brokerages have issued 1 year price targets for Harpoon Therapeutics' stock. Their forecasts range from $25.00 to $35.00. On average, they expect Harpoon Therapeutics' share price to reach $29.00 in the next year. This suggests a possible upside of 33.7% from the stock's current price. View analysts' price targets for Harpoon Therapeutics.

Has Harpoon Therapeutics been receiving favorable news coverage?

News articles about HARP stock have been trending very negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Harpoon Therapeutics earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutHarpoon Therapeutics.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 245,300 shares, a decrease of 21.9% from the April 30th total of 314,100 shares. Based on an average daily volume of 80,800 shares, the days-to-cover ratio is currently 3.0 days. Currently, 1.7% of the shares of the stock are sold short. View Harpoon Therapeutics' Current Options Chain.

Who are some of Harpoon Therapeutics' key competitors?

Some companies that are related to Harpoon Therapeutics include Bill.com (RVMD), SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Cortexyme (CRTX), Twist Bioscience (TWST), Regenxbio (RGNX), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), I-Mab (BDTX), Mesoblast (MESO), Beam Therapeutics (BEAM), Translate Bio (TBIO), Coherus Biosciences (CHRS), NanoString Technologies (NSTG) and Passage Bio (PASG). View all competitors.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Tcr2 Therapeutics (TCRR), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA) and Stoke Therapeutics (STOK).

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:

Dr. Luke B. Evnin, Chairman (Age 56)
Dr. Gerald McMahon, Pres, CEO & Director (Age 64)
Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 51)
Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)
Ms. Georgia L. Erbez, Chief Financial Officer (Age 52)

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.21%), Soleus Capital Management L.P. (1.88%), DAFNA Capital Management LLC (0.59%), Nuveen Asset Management LLC (0.58%), State Street Corp (0.58%) and Bailard Inc. (0.46%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, Holger Wesche, Luke Evnin, Mark Chin, Natalie Sacks and Patrick Baeuerle. View institutional ownership trends for Harpoon Therapeutics.

Which institutional investors are selling Harpoon Therapeutics stock?

HARP stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, and Deutsche Bank AG. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Bioscience Plc Arix, Holger Wesche, Mark Chin, Natalie Sacks, and Patrick Baeuerle. View insider buying and selling activity for Harpoon Therapeutics.

Which institutional investors are buying Harpoon Therapeutics stock?

HARP stock was bought by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., BlackRock Inc., DAFNA Capital Management LLC, Nuveen Asset Management LLC, Bailard Inc., Squarepoint Ops LLC, State Street Corp, and Geode Capital Management LLC. Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Georgia Erbez, Gerald Phd Mcmahon, and Luke Evnin. View insider buying and selling activity for Harpoon Therapeutics.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $21.69.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $542.21 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is www.harpoontx.com.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff